Unknown

Dataset Information

0

Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.

ABSTRACT: High grade serous ovarian carcinoma (HGSC) without identifiable serous tubal intraepithelial carcinoma (STIC) within the fallopian tube (FT) occurs in approximately 50% of patients. The objective of this study was to use a multisite tumor sampling approach to study HGSC with and without STIC. RNAseq analysis of HGSC samples collected from multiple sites e.g. ovary, FT and peritoneum, revealed moderate levels of intrapatient heterogeneity in gene expression that could influence molecular profiles. Mixed-model ANOVA analysis of gene expression in tumor samples from patients with multiple tumor sites (n?=?13) and patients with a single site tumor sample (n?=?11) to compare HGSC-STIC to HGSC-NOSTIC identified neurotensin (NTS) as significantly higher (> two-fold change, False Discovery Rate (FDR)?

SUBMITTER: Norris EJ 

PROVIDER: S-EPMC6619390 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.

Norris Eric J EJ   Zhang Qing Q   Jones Wendell D WD   DeStephanis Darla D   Sutker Ashley P AP   Livasy Chad A CA   Ganapathi Ram N RN   Tait David L DL   Ganapathi Mahrukh K MK  

The Journal of pathology 20190514 3

High grade serous ovarian carcinoma (HGSC) without identifiable serous tubal intraepithelial carcinoma (STIC) within the fallopian tube (FT) occurs in approximately 50% of patients. The objective of this study was to use a multisite tumor sampling approach to study HGSC with and without STIC. RNAseq analysis of HGSC samples collected from multiple sites e.g. ovary, FT and peritoneum, revealed moderate levels of intrapatient heterogeneity in gene expression that could influence molecular profiles  ...[more]

Similar Datasets

Unknown CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma.
| S-EPMC6557162 | biostudies-literature
Unknown TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions.
| S-EPMC4782784 | biostudies-other
Unknown Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma.
| S-EPMC5645359 | biostudies-literature
Unknown Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models.
| S-EPMC4609247 | biostudies-literature
Transcriptomics Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma
2017-08-01 | GSE102094 | GEO
Unknown Upfront debulking surgery for high-grade serous ovarian carcinoma: current evidence.
| S-EPMC7812243 | biostudies-literature
Genomics Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma [CNV]
2017-08-01 | GSE102085 | GEO
Transcriptomics Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma [RNA-Seq]
2017-08-01 | GSE102073 | GEO
Genomics Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma [miRNA expression]
2017-07-28 | GSE101976 | GEO
Unknown Identification of candidate genes associated with tubal origin of high-grade serous ovarian cancer.
| S-EPMC5920857 | biostudies-literature